D. Tormene (1), E. Grandone (2), V. De Stefano (3), A. Tosetto (4), G. Palareti (5), M. Margaglione (6), G. Castaman (4), E. Rossi (3), A. Ciminello (3), L. Valdrè (5), C. Legnani (5), G. L. Tiscia (2), V. Bafunno (6), S. Carraro (1), F. Rodeghiero (4), P. Simioni (1)
(1) Department of Cardiologic, Thoracic and Vascular Sciences, 2nd Chair of Internal Medicine, University of Padua, Padua, Italy; (2) Thrombosis & Haemostasis Unit, IRCCS ²Casa Sollievo della Sofferenza², S. Giovanni Rotondo, Foggia, Italy; (3) Department of Hematology, Catholic University, Rome, Italy; (4) Department of Hematology, San Bortolo Hospital, Vicenza, Italy; (5) Department of Angiology and Coagulation Disorders, University of Bologna, Italy; (6) Medical Genetics, University of Foggia, Foggia, Italy
Whether the administration of low-molecular-weight heparin (LMWH) during pregnancy is effective in preventing obstetric complications and pregnancy-related venous thromboembolism (VTE) in women who are carriers of factor V Leiden (FVL) and/or prothrombin variant G20210A (PTm) is controversial. This observational study investigated the possible efficacy of pharmacological treatment with LMWH ± aspirin (ASA) in pregnancy outcomes in 1,011 pregnancies of 416 women with thrombophilia (FVL and/or PTm). Most patients were chosen on the basis of previous obstetrical complications (36%), or because of familial or personal history of venous/arterial thromboembolism (28% and 18%, respectively); 74 patients (18%) were incidentally identified. The outcome was evaluated according to the type of treatment and of the period of pregnancy when the treatment was started. After adjustment for observation before and after diagnosis of thrombophilia, previous miscarriages and VTE, parity, age and centre, we observed that LMWH had a protective effect on miscarriages (odds ratio [OR] 0.52, 95% confidence interval [CI] 0.29–0.94) and VTE (OR 0.05, 95% CI 0.01–0.21). ASA appeared to have no effect on the prevention of obstetric complications and VTE. A nested analysis performed in 116 women with two or more obstetric complications confirmed that the highest number of live births was recorded in the group under LMWH prophylaxis (OR 0.19, 95% CI 0.05–0.75). These results suggest that LMWH prophylaxis reduces the risk of obstetric complications in carriers of FVL and/or PTm, particularly in those with previous obstetric events. Furthermore, LMWH prophylaxis reduces the risk of pregnancy-related VTE.
venous thromboembolism, low-molecular-weight heparin, pregnancy, Obstetric complications
Rupert M. Bauersachs1, Joachim Dudenhausen2, Andree Faridi3, Thorsten Fischer4, Samson Fung5, Ulrich Geisen6, Job Harenberg7, Eberhard Herchenhan8, Franz Keller9, Bettina Kemkes-Matthes10, Helmut Schinzel11, Michael Spannagl12, Christian J. Thaler13, for the EThIG Investigators*
Thromb Haemost 2007 98 6: 1237-1245
André Kher1, Rupert Bauersachs2, Jorn Dalsgaard Nielsen3
Thromb Haemost 2007 97 4: 505-513
Karim Abou-Nassar1, Michael J. Kovacs2, Susan R. Kahn3, Philip Wells1, Steve Doucette1, Tim Ramsay1, Anne Marie Clement1, Rshmi Khurana4, Karen MacKinnon2, Mark Blostein5, Susan Solymoss6, John Kingdom7, Matthew Sermer7, Evelyne Rey8, Marc Rodger1 for the TIPPS investigators
Thromb Haemost 2007 98 1: 163-171
Women with atrial fibrillation have a much higher risk for thromboembolic stroke than men suffering...
Atrial fibrillation is the commonest heart rhythm condition. Women with atrial fibrillation...
Prothrombin complex concentrates (PCC) can rapidly normalise prolonged prothrombin time, induced...